BioSpace News Archive

Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced that it will release financial results for its 2021 first quarter on Monday, May 10, 2021 before the open of the U.S. financial markets.

Neovasc, Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN) today announced that the journal EuroIntervention has published an article entitled, “Coronary Sinus Reducer Implantation Results in Improved Oxygen Kinetics at Cardiopulmonary Exercise Test in Patients with Refractory Angina.”

Neurelis, Inc., announced today that it is presenting five posters at the American Academy of Neurology (AAN) Annual Meeting being held virtually from April 17 through April 22.

Citrine Medicine, a China-based rare disease therapeutics company, and Sinopharm Group, a Chinese pharmaceutical company, today announced a strategic partnership to accelerate the commercialization of rare disease drugs in China.

Stand Up To Cancer® and Mirati Therapeutics Inc. – a late-stage targeted oncology company – announced that Mirati will contribute a $4 million grant to SU2C to develop new approaches to treat patients with KRAS mutant cancers, as a part of the SU2C Catalyst® program.

Therapeutic Solutions International, Inc., (OTC Markets: TSOI), announced today data implicating a key role in the protein Brain Derived Neurotrophic Factor (BDNF) in the therapeutic activities of NarcoStem™, an umbilical cord blood derived biologic demonstrated to possess positive animal data in preclinical models of addiction and drug induced brain damaged.

CSA Medical, Inc., today announced that Wissam Abouzgheib, MD, chief of pulmonary medicine at Cooper University Health Care, Camden, New Jersey, has joined the SPRAY-CB Study investigating a new device treatment for COPD with Chronic Bronchitis.

More than 1,500 expected at premier research community event focusing on the role technology plays enabling research sites as they transform clinical research to make it safer, smarter, and faster

Precision Medicine Company adyn Raises $2.5M Seed Funding for Personalized Birth Control Empowers women with personalized birth control recommendations aimed to minimize medication side effects, including blood clots and depression

Zynex, Inc. (Nasdaq: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, stroke rehabilitation, cardiac monitoring and neurological diagnostics, announced today that it will host the Company’s 2021 first quarter earnings investor webcast on Thursday,